Clinical Outcomes and Donor-specific Antibody Rebound 5 y After Kidney Transplant Enabled by Imlifidase Desensitization
Background. Imlifidase is an IgG-cleaving endopeptidase conditionally approved in Europe for desensitization of highly sensitized patients before kidney transplantation. We present 5-y outcomes and donor-specific antibody (DSA) levels for clinical trial participants from a single site who received i...
Saved in:
Main Authors: | Ian S. Jaffe, BS, Anna Runström, MSc, Vasishta S. Tatapudi, MD, Elaina P. Weldon, MSN, ACNP-BC, Cecilia L. Deterville, MS, Rebecca A. Dieter, PharmD, Robert A. Montgomery, MD, DPhil, Bonnie E. Lonze, MD, PhD, Massimo Mangiola, PhD |
---|---|
Format: | Article |
Language: | English |
Published: |
Wolters Kluwer
2025-02-01
|
Series: | Transplantation Direct |
Online Access: | http://journals.lww.com/transplantationdirect/fulltext/10.1097/TXD.0000000000001752 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Rapid food desensitization associated with omalizumab before oral immunotherapy
by: Bruna Giavina-Bianchi, MD, et al.
Published: (2025-02-01) -
Reply
by: Denis Vincent, MD, PhD, et al.
Published: (2025-05-01) -
A large pruritic plaque in a patient with 2 kidney transplants
by: Chiel F. Ebbelaar, MD, PharmD, et al.
Published: (2025-03-01) -
Homologous In-Radiolabeled Platelet Survival and Sequestration Exploration for Refractory Immunologic Thrombocytopenic purpura in Children: A Strategy to Avoid Unnecessary Splenectomy
by: Julien Dubois PharmD, et al.
Published: (2024-11-01) -
Examining Symptom Management and Quality of Life of Loop Diuretic-Induced Overactive Bladder Among Heart Failure Patients: Physician and Patient Perspectives
by: Xin Pan PharmD, MPH, et al.
Published: (2025-02-01)